Synthesis and evaluation of 5-HT3 receptor antagonist [11C]KF17643

Nuclear Medicine and Biology

Volumn 23, Issue 3, 1996, Pages 285-290

  Ishiwata, Kiichi ^a   Saito, Noriko ^a,b   Yanagawa, Koji ^c   Furuta, Riko ^a   Ishii, Shin Ichi ^a   Kiyosawa, Motohiro ^d   Homma, Yoshio ^b   Ishii, Kenji ^a   Suzuki, Fumio ^c   Senda, Michio ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

5 HT3 receptor; PET; Serotonin

Indexed keywords

CARBON 11; KF 17643; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN; CONTROLLED STUDY; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MOUSE;

ANIMALS; AUTORADIOGRAPHY; BRAIN; CARBON RADIOISOTOPES; HYDROCARBONS, IODINATED; INDICATORS AND REAGENTS; ISOTOPE LABELING; MALE; MICE; MICE, INBRED STRAINS; QUINOLINES; RATS; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; TROPANES;

EID: 0029938303     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(95)02079-9     Document Type: Article

References (30)

1. Andrews P. L. R., Rapeport W. G. and Sanger G. J. (1988) Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol. Sci. 9, 334-341.
2. 3H]-(S)-zacopride in the forebrain of rats. Neuropharmacology 29, 1037-1045.
3. 3 receptor antagonist. Appl. Radiat. Isot. 43, 509-516.
4. Boess F. G. and Martin I. L. (1994) Molecular biology of 5-HT receptors. Neuropharmacology 33, 275-317.
5. 3 receptor radioligand: distribution, kinetics and binding in the brain of the baboon. Neuropharmacology 32, 65-71.
6. 3 receptors. Pharmac. Ther. 47, 181-202.
7. Costall B., Jones B. J., Kelly M. E., Naylor R. J., Onaivi E. S. and Tyers M. B. (1990b) Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmac. Biochem. Behav. 36, 339-344.
8. 3 agonists and antagonists. Rev. Neurosci. 2, 41-65.
9. Crouzel C., Guillaume M., Barré L., Lemaire C. and Pike V. W. (1992) Ligands and tracers for PET studies of the 5-HT system - current status. Nucl. Med. Biol. 19, 857-870.
10. 3 receptors are membrane ion channels. Nature 339, 706-709.
11. Fozard J. R. and Mwaluko G. M. P. (1976) Mechanism of the indirect sympathomimetic effect of 5-hydroxytryptamine on the isolated heart of the rabbit. Br. J. Pharmacol. 57, 115-125.
12. 3H]dopa in various regions of the brain. J. Neurochem. 13, 655-669,
13. Hartig P. (1989) Molecular biology of 5-HT receptors. Trends Pharmacol. Sci. 10, 64-69.
14. 3 receptor antagonists. 1. New quinoline derivatives. J. Med. Chem. 35, 4893-4902.
15. 11C]YM060. Appl. Radiat. Isot. 46, 907-910.
16. 11C]semotiadil, a benzothiazine calcium antagonist. Appl. Radiat. Isot. 45, 439-443.
17. 3 receptor antagonist. Br. J. Pharmacol. 93, 985-993.
18. Julius D. (1991) Molecular biology of serotonin receptors. Ann. Rev. Neurosci. 14, 335-360.
19. 3 receptors in rat brain using radioligand binding. Nature 330, 746-748.
20. 3H]zacopride as radioaligands. Synapse 10, 271-281.
21. 3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet 1, 1198.
22. 3 receptor, a serotonin-gated ion channel. Science 254, 432-437.
23. Martin G. R. and Humphrey P. P. A. (1994) Receptors for 5-hydroxytryptamine: Current perspectives on classification and nomenclature. Neuropharmacology 33, 261-273.
24. Olofson R. A., Schnur R. C. and Pepe J. P. (1977) Selective N-dealkylation of tertiary amines with vinyl chloroformate: An improved synthesis of naloxone. Tetrahedron Lett. 18, 1567-1570.
25. Olofson R. A. and Jean-Pierre S. (1984) A new reagent, for the selective, high-yield N-dealkylation of tertiary amines: improved syntheses of naltrexone and nalbuphine. J. Org. Chem. 49, 2081-2082,
26. 3 receptor. Appl. Radiat. Isot. 43, 1369-1373.
27. 3H]meta-chlorophenylbiguanide. Eur. J. Pharmacol. 243, 13-18.
28. 3H]ICS 205-930. Neuroscience 31, 393-400.
29. White A., Corn T. H., Feetham C. and Faulconbridge C. (1991) Ondansetron in the treatment of schizophrenia. Lancet 337, 1173.
30. 3 receptors mediate rapid responses in cultured hippocampus and a clonal cell line. Neuron 1, 615-621.